FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2892283381> ?p ?o ?g. }

• W2892283381 abstract "Objective: To assess whether serum neurofilaments light chains (Nfl) are a reliable biomarker for the early recognition of PML during natalizumab treatment. Background: The monoclonal antibody natalizumab is a highly effective treatment for patients with multiple sclerosis (MS). However, the drug is associated with increased risk of progressive multifocal leukoencephalopathy (PML), a severe infection of the CNS caused by the reactivation of JC virus. Huge efforts have been made to improve risk stratification algorithms and to facilitate early disease recognition, but no serum biomarker is currently available for the condition. Design/Methods: Patients were recruited from 2 European MS cohorts. Of 213 patients with MS, 102 had been treated with natalizumab (9–84 months), 37 received other immune-modulatory treatments, and 74 were untreated. 12 healthy controls (HC) were also enrolled. We had access to samples from 25 natalizumab PML patients. Serum NfL concentration was assessed using an ECL immunoassay. Results: NFL levels were higher in treated (18.0 ± 11.8 pg/ml) or untreated (22.7 ± 17.5 pg/ml) MS patients than in HC (10.8 ± 6.9 pg/ml) (p 0.05 and 0.04 respectively), and were associated with the presence of recent clinical relapses or enhancing lesions at MRI (p 0.01). Natalizumab treated patients had similar Nfl levels (17.0 ± 10.4 pg/ml) to that of other MS patients. At the onset of PML, serum Nfl levels were highly increased (346.1 ± 95.9 pg/ml, p Conclusions: If replicated in future studies, serum NfL may represent a reliable and easily accessible biomarker of early PML detection in natalizumab treated MS patients. Disclosure: Dr. Dalla Costa has nothing to disclose. Dr. Martinelli has nothing to disclose. Dr. Finardi has nothing to disclose. Dr. Sangalli has nothing to disclose. Dr. Colombo has nothing to disclose. Dr. Moiola has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Sanofi-Genzyme, Novartis, Teva, Merck-Serono, Biogen, Roche, Excemed. Dr. Cinque has nothing to disclose. Dr. Kolb has nothing to disclose. Dr. Haghikia has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Bayer, Genzyme and Biogen. Dr. Gold has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Teva Pharmaceutical Industries Ltd., Biogen Idec, Bayer Schering Pharma, and Novartis. Dr. Gold has received personal compensation in an editorial capacity for Therapeutic Advances in Neurological Diseases, Experimental Neurology and the Journal of Neuroimmunology. Dr. Gold has received research support from Teva Pharmaceutical Industries Ltd., Biogen Idec, Bayer Schering Pharma, Genzyme, Merck Serono, and Novartis. Dr. Furlan has nothing to disclose. Dr. Comi has nothing to disclose." @default.
• W2892283381 created "2018-09-27" @default.
• W2892283381 creator A5004879715 @default.
• W2892283381 creator A5006120476 @default.
• W2892283381 creator A5010538416 @default.
• W2892283381 creator A5013988168 @default.
• W2892283381 creator A5028943503 @default.
• W2892283381 creator A5043499649 @default.
• W2892283381 creator A5050119083 @default.
• W2892283381 creator A5055711554 @default.
• W2892283381 creator A5062220148 @default.
• W2892283381 creator A5080950690 @default.
• W2892283381 creator A5085639343 @default.
• W2892283381 creator A5088528588 @default.
• W2892283381 date "2018-04-10" @default.
• W2892283381 modified "2023-09-24" @default.
• W2892283381 title "Serum neurofilament light chain levels are increased at the onset of PML in natalizumab treated MS patients (P1.383)" @default.
• W2892283381 hasPublicationYear "2018" @default.
• W2892283381 type Work @default.
• W2892283381 sameAs 2892283381 @default.
• W2892283381 citedByCount "0" @default.
• W2892283381 crossrefType "journal-article" @default.
• W2892283381 hasAuthorship W2892283381A5004879715 @default.
• W2892283381 hasAuthorship W2892283381A5006120476 @default.
• W2892283381 hasAuthorship W2892283381A5010538416 @default.
• W2892283381 hasAuthorship W2892283381A5013988168 @default.
• W2892283381 hasAuthorship W2892283381A5028943503 @default.
• W2892283381 hasAuthorship W2892283381A5043499649 @default.
• W2892283381 hasAuthorship W2892283381A5050119083 @default.
• W2892283381 hasAuthorship W2892283381A5055711554 @default.
• W2892283381 hasAuthorship W2892283381A5062220148 @default.
• W2892283381 hasAuthorship W2892283381A5080950690 @default.
• W2892283381 hasAuthorship W2892283381A5085639343 @default.
• W2892283381 hasAuthorship W2892283381A5088528588 @default.
• W2892283381 hasConcept C126322002 @default.
• W2892283381 hasConcept C203014093 @default.
• W2892283381 hasConcept C2779150272 @default.
• W2892283381 hasConcept C2780640218 @default.
• W2892283381 hasConcept C2780644213 @default.
• W2892283381 hasConcept C2781004633 @default.
• W2892283381 hasConcept C2781137167 @default.
• W2892283381 hasConcept C2781197716 @default.
• W2892283381 hasConcept C55493867 @default.
• W2892283381 hasConcept C71924100 @default.
• W2892283381 hasConcept C86803240 @default.
• W2892283381 hasConcept C90924648 @default.
• W2892283381 hasConceptScore W2892283381C126322002 @default.
• W2892283381 hasConceptScore W2892283381C203014093 @default.
• W2892283381 hasConceptScore W2892283381C2779150272 @default.
• W2892283381 hasConceptScore W2892283381C2780640218 @default.
• W2892283381 hasConceptScore W2892283381C2780644213 @default.
• W2892283381 hasConceptScore W2892283381C2781004633 @default.
• W2892283381 hasConceptScore W2892283381C2781137167 @default.
• W2892283381 hasConceptScore W2892283381C2781197716 @default.
• W2892283381 hasConceptScore W2892283381C55493867 @default.
• W2892283381 hasConceptScore W2892283381C71924100 @default.
• W2892283381 hasConceptScore W2892283381C86803240 @default.
• W2892283381 hasConceptScore W2892283381C90924648 @default.
• W2892283381 hasLocation W28922833811 @default.
• W2892283381 hasOpenAccess W2892283381 @default.
• W2892283381 hasPrimaryLocation W28922833811 @default.
• W2892283381 hasRelatedWork W1427736029 @default.
• W2892283381 hasRelatedWork W1516922859 @default.
• W2892283381 hasRelatedWork W1578604843 @default.
• W2892283381 hasRelatedWork W1690394439 @default.
• W2892283381 hasRelatedWork W1855849411 @default.
• W2892283381 hasRelatedWork W2172569637 @default.
• W2892283381 hasRelatedWork W2415726952 @default.
• W2892283381 hasRelatedWork W2615311368 @default.
• W2892283381 hasRelatedWork W2686867070 @default.
• W2892283381 hasRelatedWork W274439164 @default.
• W2892283381 hasRelatedWork W2788846357 @default.
• W2892283381 hasRelatedWork W2789577374 @default.
• W2892283381 hasRelatedWork W2810371342 @default.
• W2892283381 hasRelatedWork W3024247555 @default.
• W2892283381 hasRelatedWork W3033147336 @default.
• W2892283381 hasRelatedWork W3158740475 @default.
• W2892283381 hasRelatedWork W3172330283 @default.
• W2892283381 hasRelatedWork W3199103342 @default.
• W2892283381 hasRelatedWork W3207549879 @default.
• W2892283381 hasRelatedWork W860202733 @default.
• W2892283381 hasVolume "90" @default.
• W2892283381 isParatext "false" @default.
• W2892283381 isRetracted "false" @default.
• W2892283381 magId "2892283381" @default.
• W2892283381 workType "article" @default.